WASHINGTON (Reuters) - Merck & Co's experimental insomnia drug is safe and effective at the lower of two doses studied but not at the higher, a panel of medical experts said on Wednesday. The panel, which advises the U.S. Food and Drug Administration on matters related to central nervous system disorders, voted 13-3, with one abstention, that the drug, suvorexant, is safe for elderly patients at 15 milligrams a day, and is safe for non-elderly adults at 20 milligrams. ...
Click here to read the rest
No comments:
Post a Comment